Nanomedicine News

RSS

NanGenex Completes First Round in Vivo Testing of NanoActive Nanoformulations of Block-Buster Drugs

NanGenex Inc., the proprietary NanoActive™ continuous flow technology platform company, has completed the first round in vivo testing of NanoActive™ nanoformulations of block-buster drugs. Low water solub...

28 Jul 2010

SurModics Partners with EGEN for Controlled Release of siRNA Nanocomplexes

SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nuclei...

28 Jul 2010

Scientists Pack Cisplatin into Nanoparticles for Use as Chemotherapy Drug

One of the first chemotherapy drugs given to patients diagnosed with cancer — especially lung, ovarian or breast cancer — is cisplatin, a platinum-containing compound that gums up tumor cells’ DNA. Cisplatin does a good job of killing those tumor cells, but it can also seriously damage the kidneys, which receive high doses of cisplatin because they filter the blood.

28 Jul 2010

New Laser-Activated Carbon Nanoparticle System for Intracellular Drug Delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.

28 Jul 2010

NanoActive Formulation Boosts Oral Bioavailability of Drugs, Shows In Vivo Data

From Tavanta Therapeutics 28 Jul 2010

Abraxis Receives Approval to Sell ABRAXANE in Japan

Abraxis BioScience, Inc., a fully integrated, global biotechnology company, today announced that Taiho Pharmaceutical Co., Ltd. has received approval from the Ministry of Health, Labor and Welfare to market ABRAXANE® IV Infusion 100 mg, Paclitaxel Injection (Suspension with Albumin), for use in the treatment of breast cancer.

27 Jul 2010

New Nano-Based Technology from Senior Scientific Enables Early Cancer Detection

Manhattan Scientifics, Inc. said today that a July 20th New York Times article titled “Prone to Error: Earliest Steps to Find Cancer” highlights the potential value of the early cancer detection technology developed by Senior Scientific, LLC and licensed by Manhattan Scientifics.

From Manhattan Scientifics Inc. 27 Jul 2010

New Book Available on Microfluidic Devices for Nanotechnology

Research and Markets (http://www.researchandmarkets.com/research/d74bde/microfluidic_devic) has announced the addition of John Wiley and Sons Ltd's new book "Microfluidic Devices in Nanotechnology: Applications" to their...

26 Jul 2010

U.S. Demand for Nano-Based Medical Products to Increase Over 17%

Reportlinker.com announces that a new market research report is available in its catalogue: Nanotechnology in Health Care. US demand to rise more than 17% annually thru 2014 US demand for nanotechnology medical pr...

26 Jul 2010

Advanced Biophotonic Method Helps to Study Cellular Changes at Molecular Levels

Apoptosis, programmed cell death, is essential to normal development, healthy immune system function, and cancer prevention. The process dramatically transforms cellular structures but the limitations of conventional microscopy methods have kept much about this structural reorganization a mystery.

23 Jul 2010